Radiopharm Theranostics Limited (ASX: RAD) - Share Price

- Current share price for RAD : $0.004

Radiopharm Theranostics Limited (RAD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a clinical stage radiotherapeutics organisation developing a platform of radiopharmaceutical products for diagnostic and therapeutic use in areas of unmet medical need. The development pipeline consists of platform technologies that include peptides, small molecules, and monoclonal antibodies for cancer applications.

RAD General Information ⁺

ASX Code	RAD
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	18
RAD Share Price	$0.004
Day High	$0.004
Day Low	$0.004
Last Close	$0.004
RAD Share Price Movement	- ( No change )

Prices as at 16:40, 13 Nov 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Radiopharm Theranostics Limited (RAD) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Radiopharm Theranostics Limited (RAD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Radiopharm Theranostics Limited (RAD) price-sensitive announcements

RAD - RAD Alignment with US FDA for Development of RAD101

Radiopharm Theranostics announced that, following its End-of-Phase 2 meeting with the U.S.

Radiopharm Theranostics Limited (RAD)
4 Nov 2026 | 8:49 AM

RAD - Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics Limited’s Quarterly Activities and Appendix 4C Cash Flow Report fo

Radiopharm Theranostics Limited (RAD)
30 Oct 2026 | 4:34 PM

RAD - Radiopharm receives $8M advance on FY26 R&D tax incentive

Radiopharm Theranostics Limited announced it has received an $8 million advance from Rockf

Radiopharm Theranostics Limited (RAD)
26 Oct 2026 | 3:53 PM

RAD - Appendix 4E and Preliminary Final Report

Radiopharm Theranostics Limited’s Appendix 4E Preliminary Final Report for the Australian

Radiopharm Theranostics Limited (RAD)
28 Aug 2026 | 4:07 PM

Radiopharm Theranostics Limited (RAD) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	Change of Director's Interest Notices x 4	11 Nov 2026 1:33PM	$0.004	$0.004	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	RAD Alignment with US FDA for Development of RAD101	4 Nov 2026 8:49AM	$0.003	$0.004	risen by 33.33%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	Quarterly Activities/Appendix 4C Cash Flow Report	30 Oct 2026 4:34PM	$0.005	$0.004	fallen by 20%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	Notice of Annual General Meeting/Proxy Form	27 Oct 2026 11:54AM	$0.004	$0.004	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	Radiopharm receives $8M advance on FY26 R&D tax incentive	26 Oct 2026 3:53PM	$0.005	$0.004	fallen by 11.11%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$19	Notification regarding unquoted securities - RAD	20 Oct 2026 3:52PM	$0.005	$0.004	fallen by 11.11%

RAD Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$1.00	-14.50%	0.00%	0.0%
2027F	C2	-$1.20	-36.80%	0.00%	0.0%
2026A	-$58.62	-$1.90	17.80%	0.00%	0.0%

RAD Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
CSL Limited (CSL)	$98,156M	0.7309	-0.4387	0.0602	12.6717	22.5759	21.2945	2.08%	2.09%	2.15%
Mesoblast Limited (MSB)	$2,544M	-0.4501	0.0000	0.0000	0.0000	0.0000	888.6364	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,886M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Radiopharm Theranostics Limited (RAD)	$19M	0.1783	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,663M	-1.3893	0.0000	-0.5229	0.0000	160.9871	337.4384	0.00%	0.00%	0.00%

RAD Directors

Name	Position	Start Date
Mr Riccardo Canevari	Chief Executive Officer, Managing Director	13 Sep 2021
Mr Paul Alex Hopper	Executive Chairman, Founder, Executive Director	11 Feb 2021
Mr Ian Turner	Non-Executive Director	1 Apr 2021
Ms Hester Larkin	Non-Executive Director	3 Feb 2022
Mr Noel Donnelly	Non-Executive Director	1 Oct 2024
Mr Bruce Goodwin	Non-Executive Director	19 Nov 2025

Radiopharm Theranostics Limited (RAD) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
9 Nov 2026	HOPPER, Paul	Sell	Indirect Shares	1,111,111	$0.003	$3,333.333
5 Nov 2026	TURNER, Ian	Sell	Direct Shares	1,111,111	$0.004	$3,913.889
5 Nov 2026	GOODWIN, Bruce	Sell	Indirect Shares	1,111,111	$0.004	$3,913.889

See all changes in directors' interest & trades for Radiopharm Theranostics Limited (RAD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAD Management

Name	Position
Aaron Laurita	CFO
Dimitris Voliotis	Chief Medical Officer
Amritha Sushil	Joint Company Secretary
Nathan Kim -liung Jong	Joint Company Secretary

RAD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Radiopharm Theranostics Limited (RAD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
537,958,513 (15.18%)	Lantheus Omega, LLC

RAD Calendar of Events

Date	Event
29 September 2027	Report (Annual)
27 August 2027	Report (Prelim)
26 February 2027	Report (Interim)
25 November 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us